Broad Coverage Lyme Ab Assay

About the Test

The Lyme Broad Coverage Antibody (BCA) Assay is a qualitative test designed to detect IgM and IgG antibodies to Lyme Borreliae group–specific antigens in human serum. The sensitivity of the Lyme BCA Assay is 90%, and the specificity is 97%. This test is unavailable for patients over 65 when ordered through physician services.

Biomarkers

Borrelia burgdorferi IgG

Borrelia burgdorferi IgM

Biomarker name

Related Articles

Related Tests

Lyme Disease Antibody w/ Reflex to Blot (IgG, IgM)

 by 

Access Med Labs

Serum

This test detects antibodies to the bacterium Borrelia burgdorferi. Lyme disease is caused by Borrelia burgdorferi and is transmitted to humans through the bite of infected black-legged ticks. Immunoblot testing will confirm a detected screening result.

Immunoserology of Lyme Panel B

 by 

Immunosciences Lab

Serum

This panel uses Immunosciences Lab's patented ELISA methodology, as well as the Western Blot technique, to measure 26 different antibodies against Lyme-specific antigens, Borrelia subspecies, and co-infections. It can detect active and chronic Lyme disease, including Lyme arthritis and neuroborreliosis that may be confused with multiple sclerosis.

Epstein-Barr Virus (EBV) Panel

 by 

Immunosciences Lab

Serum

EBV contributes to more than 30 autoimmune disorders. Detection of IgG or IgM antibodies to various EBV antigens indicates either past infection, primary reactivation, or re-infection with Epstein-Barr Virus or Herpes Type 4.

B. burgdorferi IgG, IgM by Western Blot

 by 

Immunosciences Lab

Serum

This test confirms the presence of ongoing Lyme disease based on CDC criteria.

Lyme Disease, Line Blot

 by 

Labcorp

Serum

This test is used to detect antibodies specific for B. burgdorferi. This test is intended as the second step in testing serum samples found to have been equivocal or positive using an ELISA or IFA test.